U.S. markets closed

Rocket Pharmaceuticals, Inc. (RCKT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
55.58+3.72 (+7.17%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close51.86
Open51.94
Bid49.00 x 900
Ask60.75 x 1000
Day's Range50.04 - 56.25
52 Week Range9.01 - 67.48
Volume490,053
Avg. Volume756,125
Market Cap3.367B
Beta (5Y Monthly)1.69
PE Ratio (TTM)N/A
EPS (TTM)-2.52
Earnings DateFeb 25, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est72.64
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Business Wire

    Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational Results

    Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today reports financial and operational results for the fourth quarter and year ended December 31, as well as guidance for anticipated 2021 milestones.

  • Benzinga

    Benzinga's Top Ratings Upgrades, Downgrades For February 18, 2021

    Upgrades According to Ladenburg Thalmann, the prior rating for Invitae Corp (NYSE:NVTA) was changed from Neutral to Buy. For the fourth quarter, Invitae had an EPS of $0.63, compared to year-ago quarter EPS of $0.63. At the moment, the stock has a 52-week-high of $61.59 and a 52-week-low of $7.42. Invitae closed at $47.87 at the end of the last trading period. According to Maxim Group, the prior rating for Titan Pharmaceuticals Inc (NASDAQ:TTNP) was changed from Hold to Buy. The current stock performance of Titan Pharmaceuticals shows a 52-week-high of $4.30 and a 52-week-low of $0.09. Moreover, at the end of the last trading period, the closing price was at $3.55. According to Berenberg, the prior rating for Varonis Systems Inc (NASDAQ:VRNS) was changed from Hold to Buy. In the fourth quarter, Varonis Systems showed an EPS of $0.34, compared to $0.09 from the year-ago quarter. The stock has a 52-week-high of $226.00 and a 52-week-low of $48.95. At the end of the last trading period, Varonis Systems closed at $200.82. According to Credit Suisse, the prior rating for Mohawk Industries Inc (NYSE:MHK) was changed from Underperform to Neutral. Mohawk Industries earned $3.54 in the fourth quarter, compared to $2.25 in the year-ago quarter. At the moment, the stock has a 52-week-high of $178.19 and a 52-week-low of $56.62. Mohawk Industries closed at $168.84 at the end of the last trading period. For Wells Fargo & Co (NYSE:WFC), JP Morgan upgraded the previous rating of Underweight to Neutral. In the fourth quarter, Wells Fargo showed an EPS of $0.64, compared to $0.93 from the year-ago quarter. At the moment, the stock has a 52-week-high of $48.31 and a 52-week-low of $20.76. Wells Fargo closed at $36.56 at the end of the last trading period. Berenberg upgraded the previous rating for STMicroelectronics NV (NYSE:STM) from Sell to Hold. For the fourth quarter, STMicroelectronics had an EPS of $0.63, compared to year-ago quarter EPS of $0.43. At the moment, the stock has a 52-week-high of $43.02 and a 52-week-low of $14.67. STMicroelectronics closed at $41.73 at the end of the last trading period. See all analyst ratings upgrades. Downgrades According to Seaport Global, the prior rating for Andersons Inc (NASDAQ:ANDE) was changed from Buy to Neutral. In the fourth quarter, Andersons showed an EPS of $0.59, compared to $0.55 from the year-ago quarter. The stock has a 52-week-high of $29.29 and a 52-week-low of $10.00. At the end of the last trading period, Andersons closed at $27.44. For Tilray Inc (NASDAQ:TLRY), Benchmark downgraded the previous rating of Buy to Hold. Tilray earned $0.45 in the fourth quarter, compared to $0.62 in the year-ago quarter. The current stock performance of Tilray shows a 52-week-high of $67.00 and a 52-week-low of $2.43. Moreover, at the end of the last trading period, the closing price was at $31.51. For KAR Auction Services Inc (NYSE:KAR), Stephens & Co. downgraded the previous rating of Overweight to Equal-Weight. For the fourth quarter, KAR Auction Services had an EPS of $0.01, compared to year-ago quarter EPS of $0.19. The stock has a 52-week-high of $23.53 and a 52-week-low of $9.41. At the end of the last trading period, KAR Auction Services closed at $15.88. According to Baird, the prior rating for Kratos Defense & Security Solutions Inc (NASDAQ:KTOS) was changed from Outperform to Neutral. Kratos Defense & Security earned $0.14 in the third quarter, compared to $0.09 in the year-ago quarter. The current stock performance of Kratos Defense & Security shows a 52-week-high of $34.11 and a 52-week-low of $5.00. Moreover, at the end of the last trading period, the closing price was at $33.24. For TechnipFMC PLC (NYSE:FTI), UBS downgraded the previous rating of Buy to Neutral. For the third quarter, TechnipFMC had an EPS of $0.16, compared to year-ago quarter EPS of $0.12. At the moment, the stock has a 52-week-high of $17.59 and a 52-week-low of $4.49. TechnipFMC closed at $7.79 at the end of the last trading period. For Noble Midstream Partners LP (NASDAQ:NBLX), Credit Suisse downgraded the previous rating of Outperform to Neutral. Noble Midstream Partners earned $0.44 in the fourth quarter, compared to $0.65 in the year-ago quarter. At the moment, the stock has a 52-week-high of $20.60 and a 52-week-low of $1.81. Noble Midstream Partners closed at $13.97 at the end of the last trading period. See all analyst ratings downgrades. Initiations Seaport Global initiated coverage on ConnectOne Bancorp Inc (NASDAQ:CNOB) with a Buy rating. The price target for ConnectOne Bancorp is set to $27.00. In the fourth quarter, ConnectOne Bancorp showed an EPS of $0.64, compared to $0.61 from the year-ago quarter. The stock has a 52-week-high of $24.26 and a 52-week-low of $8.86. At the end of the last trading period, ConnectOne Bancorp closed at $22.71. Wedbush initiated coverage on Dream Finders Homes Inc (NASDAQ:DFH) with a Neutral rating. The price target for Dream Finders Homes is set to $21.00. The stock has a 52-week-high of $31.98 and a 52-week-low of $17.55. At the end of the last trading period, Dream Finders Homes closed at $26.14. With a Buy rating, Jefferies initiated coverage on VistaGen Therapeutics Inc (NASDAQ:VTGN). The price target seems to have been set at $6.00 for VistaGen Therapeutics. VistaGen Therapeutics earned $0.07 in the third quarter, compared to $0.15 in the year-ago quarter. At the moment, the stock has a 52-week-high of $2.94 and a 52-week-low of $0.30. VistaGen Therapeutics closed at $2.06 at the end of the last trading period. With a Hold rating, Stifel initiated coverage on McAfee Corp (NASDAQ:MCFE). The price target seems to have been set at $20.00 for McAfee. For the third quarter, McAfee had an EPS of $0.00, compared to year-ago quarter EPS of $0.02. At the moment, the stock has a 52-week-high of $22.14 and a 52-week-low of $14.80. McAfee closed at $19.28 at the end of the last trading period. With a Buy rating, Stifel initiated coverage on Cognyte Software Ltd (NASDAQ:CGNT). The price target seems to have been set at $42.00 for Cognyte Software. The stock has a 52-week-high of $33.50 and a 52-week-low of $23.75. At the end of the last trading period, Cognyte Software closed at $29.75. With a Buy rating, HC Wainwright & Co. initiated coverage on Liminal Biosciences Inc (NASDAQ:LMNL). The price target seems to have been set at $11.00 for Liminal Biosciences. In the third quarter, Liminal Biosciences earned $0.74. The stock has a 52-week-high of $31.45 and a 52-week-low of $3.51. At the end of the last trading period, Liminal Biosciences closed at $5.74. Piper Sandler initiated coverage on Infinity Pharmaceuticals Inc (NASDAQ:INFI) with an Overweight rating. The price target for Infinity Pharmaceuticals is set to $7.00. In the third quarter, Infinity Pharmaceuticals showed an EPS of $0.16, compared to $0.20 from the year-ago quarter. At the moment, the stock has a 52-week-high of $5.98 and a 52-week-low of $0.60. Infinity Pharmaceuticals closed at $3.81 at the end of the last trading period. With a Buy rating, Needham initiated coverage on TechTarget Inc (NASDAQ:TTGT). The price target seems to have been set at $115.00 for TechTarget. In the fourth quarter, TechTarget showed an EPS of $0.46, compared to $0.27 from the year-ago quarter. The stock has a 52-week-high of $101.12 and a 52-week-low of $16.82. At the end of the last trading period, TechTarget closed at $92.62. Needham initiated coverage on Rocket Pharmaceuticals Inc (NASDAQ:RCKT) with a Buy rating. The price target for Rocket Pharmaceuticals is set to $75.00. In the third quarter, Rocket Pharmaceuticals showed an EPS of $0.53, compared to $0.38 from the year-ago quarter. The stock has a 52-week-high of $67.48 and a 52-week-low of $9.01. At the end of the last trading period, Rocket Pharmaceuticals closed at $52.62. With a Buy rating, Needham initiated coverage on Generation Bio Co (NASDAQ:GBIO). The price target seems to have been set at $50.00 for Generation Bio. Generation Bio earned $0.46 in the third quarter, compared to $3.31 in the year-ago quarter. The stock has a 52-week-high of $55.72 and a 52-week-low of $18.80. At the end of the last trading period, Generation Bio closed at $31.79. See all analyst ratings initiations. See more from BenzingaClick here for options trades from BenzingaEarnings Outlook For Tremont MortgageAnalyzing The Price Action In West Pharmaceutical Servs Stock Today© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Business Wire

    Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

    Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders announces participation at the following upcoming conferences: